Academic Journal

The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis.

التفاصيل البيبلوغرافية
العنوان: The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis.
المؤلفون: G. Saruhan-Direskeneli, M. Inanc, I. Fresko, N. Akkoc, E. Dalkilic, E. Erken, Y. Karaaslan, G. Kinikli, F. Oksel, S. Pay, E. Yucel, S. P. Yentür, J. Duymaz-Tozkir, V. Yilmaz, N. Inanc, H. Yazici, M. Konice, H. Direskeneli
المصدر: Rheumatology; Dec2007, Vol. 46 Issue 12, p1842-1842, 1p
مصطلحات موضوعية: EPITOPES, RHEUMATOID arthritis, LEFLUNOMIDE, OLIGONUCLEOTIDES
مستخلص: Objectives. To investigate the role of shared epitope (SE) alleles in the short–term clinical response to leflunomide for the treatment of active RA. Methods. In an open-label, multi-centre study of 16-weeks duration, 93 patients (82% female) fulfilling ARA 1987 RA criteria were treated with leflunomide (100 mg loading dose for 3 days, then 20 mg/day as the maintenance dose). The primary efficacy criterion was the response status according to the European League Against Rheumatism (EULAR) response criteria using Disease Activity Score-28 (DAS28) activity measure. SE determinations have been undertaken by polymerase chain reaction and sequence–specific oligonucleotide genotyping methods. Results. The mean (s.d.) Disease Activity Score-28 (DAS28) was 5.1 (1.3) before the treatment, which was significantly decreased after 16 weeks [3.0 (1.1), P P = 0.04). No difference was present according to SE hetero- or homozygosity (68.4 vs 69.2%). RF was also present significantly more frequently in the SE-positive group compared with negatives (78.4 vs 57.1%, P = 0.03). However, no significant difference was observed in the prevalence of RF positivity in patients with a good clinical response (72.7 vs 63.2%, P = 0.32). Conclusions. The results suggest that HLA–DRB1 SE presence may favourably affect the outcome of leflunomide monotherapy in an unselected group of RA patients with an active disease and naive to leflunomide. [ABSTRACT FROM AUTHOR]
Copyright of Rheumatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:14620324
DOI:10.1093/rheumatology/kem278